摘要
随着中国糖尿病和抑郁症的发病率逐年上升,其共病率也在增加,这给共病患者的治疗带来了巨大挑战。临床发现,二甲双胍、利拉鲁肽、格列苯脲、格列美脲、罗格列酮等降糖药物可改善糖尿病合并抑郁症患者的葡萄糖代谢和抑郁严重程度。西格列汀、吡格列酮、胰岛素和抑郁症的关系尚存在争议。阿卡波糖、SGLT-2抑制剂的抗抑郁作用无相关研究。文章旨在探讨临床常用降糖药物的抗抑郁作用机制及潜能,为糖尿病合并抑郁症患者的治疗提供新的思路。
As the prevalence of diabetes and depression in China increases each year,so does their co-morbidity,which poses a great challenge to the treatment of co-morbid patients.Glucose-lowering drugs such as metformin,liraglutide,gliphenylurea,glimepiride,and rosiglitazone have been clinically found to improve glucose metabolism and depression severity in patients with diabetes mellitus combined with depression.The relationship between sitagliptin,pioglitazone,insulin and depression is controversial.There are no studies related to the antidepressant effects of acarbose and SGLT-2 inhibitors.The purpose of the paper is to explore the mechanism and potential of antidepressant effects of commonly used clinical hypoglycemic drugs and to provide new ideas for the treatment of patients with diabetes mellitus combined with depression.
作者
杨会军
梁华素
杨莹
YANG Hui-jun;LIANG Hua-su;YANG Ying(Department of Endocrinology,The Affiliated Hospital of Yunnan University,The Second People’s Hospital of Yunnan Province,Kunming,Yunnan,650021,China)
出处
《黑龙江医学》
2023年第5期632-636,共5页
Heilongjiang Medical Journal
基金
国家自然科学基金(81760734)
云南省教育厅科学研究基金项目(2021J0018)
云南省第二人民医院内分泌与代谢疾病临床医学中心(ZX2019-02-02)
云南省第二人民医院糖尿病血管病变预防及诊疗省创新团队(2019HC002)
昆明医科大学硕士研究生创新基金(2021S283)。
关键词
糖尿病
抑郁症
药物治疗
机制
研究进展
Diabetes mellitus
Depression
Drug treatment
Mechanisms
Advances
